CAMBRIDGE, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Novaseek Research Inc., a health IT for life sciences company, today announced that it has named Bennett Malbon as Chief Technology Officer (CTO) for the company. This is an expansion of Bennett’s current role as Vice President, Technology. As CTO, Bennett will be responsible for driving expansion of Novaseek’s Clinical Data Network for Research (CDNR) platform to meet the evolving needs of biomedical and clinical researchers.
“Novaseek is growing rapidly, and there is a strong need for someone with Bennett’s talent and vision to help drive strategy for the growth and expansion of our CDNR platform,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Bennett has a proven track record of developing comprehensive clinical data solutions for critical needs within the healthcare and life sciences industries. We are excited to have Bennett in this new position.”
“Novaseek is truly innovative in its approach and in the way it enables healthcare organizations and patients to share clinical data and biospecimens for research and provides access for biomedical and clinical researchers to well-categorized patient cohorts for translational and observations studies. I am thrilled to take it to the next level as our team leverages technology to bring better medicines to patients faster,” said Bennett.
Bennett helped found Novaseek Research in 2014, He has more than 20 years of experience in IT and software development. Prior to Novaseek, Bennett was the founding technology architect at Curaspan Health Group, which was acquired by Cardinal Health/NaviHealth in 2016, where he led development and roll-out of a patient transition network electronically connecting 600+ acute care health systems to 8000+ post-acute care providers, payers, and medical transportation services, ultimately handling transitions for approximately 20 percent of acute patients in the U.S. Additionally, Bennett worked with PatientKeeper where he oversaw platform strategy and architecture for physician portal and workflow tools, and with HealthGrid, an ambulatory EMR referral and data exchange network.
Novaseek’s CDNR is an award-winning, cloud-based platform that provides turn-key access to real world data, patients and biospecimens from a network of healthcare organizations. The CDNR platform enables analysis and prospective observation of well-categorized patient cohorts across multiple disease areas. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens with detailed clinical data using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories.
CDNR makes it possible for Novaseek and its hospital partners to serve complex requests, such as, for example, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research, often cutting out up to 12 months of observational study set up and completion and allows more hospitals and patients to participate in biomedical research.
Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics, and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies.
Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please
Media Contact: Terri Clevenger Continuum Health Communications email@example.com (203) 856-4326
Source:Novaseek Research, LLC